NETT Point

Platelet-Oriented Inhibition in New TIA and minor ischemic stroke (POINT)

POINT is a multicenter clinical trial to determine the safety and effectiveness of the combination of low-dose aspirin and a medication called clopidogrel (also known by the brand name Plavix ®) in reducing the risk of stroke, heart attacks and other complications in patients who have just had a transient ischemic attack (TIA) or minor ischemic stroke.

A TIA is a condition that produces stroke-like symptoms like sudden weakness on one side of the body or trouble speaking, but the symptoms are temporary. A minor ischemic stroke occurs when blood flow is interrupted to a part of the brain. Depending on the region of the brain affected, a stroke may cause paralysis, speech impairment, loss of memory and reasoning ability, coma, or death.

The best treatment for prevention of another stroke or TIA in patients with narrowing of one of the arteries in the brain is uncertain. A common treatment is the use of anti-clotting medications to prevent blood clots from forming in the narrowed vessel. There are a variety of medicines used for this purpose, including aspirin and clopidogrel. These medications are usually taken for the rest of a patient’s life.

This study will enroll 5841 patients at approximately one hundred and fifty different institutions; each participant will be involved in the study for 90 days.

Contact Us

RRC@mcw.edu | (414) 805-6493

Non-Discrimination Statement
The 皇家华人 (MCW) is committed to fostering a diverse community of outstanding faculty, staff, and students, as well as ensuring equal educational opportunity, employment, and access to services, programs, and activities, without regard to an individual's race, color, national origin, religion, age, disability, sex, gender identity/expression, sexual orientation, marital status, pregnancy, predisposing genetic characteristic, or military status. Employees, students, applicants or other members of the MCW community (including but not limited to vendors, visitors, and guests) may not be subjected to harassment that is prohibited by law or treated adversely or retaliated against based upon a protected characteristic. MCW’s policy as well as federal and state laws and regulations prohibit unlawful discrimination and harassment.